Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
APLMW
Apollomics
$0.02
-8.8%
$0.03
$0.01
$0.05
N/AN/A82,131 shs2,076 shs
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
$0.46
-16.3%
$0.03
$0.00
$0.62
N/AN/A493,603 shs5.19 million shs
Alpha Tau Medical Ltd. stock logo
DRTSW
Alpha Tau Medical
$0.27
-1.1%
$0.25
$0.13
$0.50
N/AN/A22,018 shs413 shs
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$0.09
-10.5%
$0.06
$0.01
$0.16
N/AN/A14,737 shs4,885 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
APLMW
Apollomics
-8.81%-9.85%-15.00%+138.00%+135.64%
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
-16.36%+4,500.00%+6,033.33%+6,566.67%+4,239.62%
Alpha Tau Medical Ltd. stock logo
DRTSW
Alpha Tau Medical
-1.11%+3.09%-2.20%+17.62%+48.33%
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
-10.49%-13.05%+56.60%+53.19%+63.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
APLMW
Apollomics
N/AN/AN/AN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Alpha Tau Medical Ltd. stock logo
DRTSW
Alpha Tau Medical
N/AN/AN/AN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
APLMW
Apollomics
0.00
N/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
0.00
N/AN/AN/A
Alpha Tau Medical Ltd. stock logo
DRTSW
Alpha Tau Medical
0.00
N/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
APLMW
Apollomics
N/AN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/A
Alpha Tau Medical Ltd. stock logo
DRTSW
Alpha Tau Medical
N/AN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$665.45KN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
APLMW
Apollomics
N/AN/A0.00N/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
Alpha Tau Medical Ltd. stock logo
DRTSW
Alpha Tau Medical
N/AN/A0.00N/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
APLMW
Apollomics
N/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/A
Alpha Tau Medical Ltd. stock logo
DRTSW
Alpha Tau Medical
N/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
APLMW
Apollomics
59N/AN/ANot Optionable
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
7N/AN/ANot Optionable
Alpha Tau Medical Ltd. stock logo
DRTSW
Alpha Tau Medical
80N/AN/ANot Optionable
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
2N/AN/ANot Optionable

Recent News About These Companies

60 Degrees Pharmaceuticals Reports Q2 2025 Earnings
60 Degrees Pharmaceuticals signs Patient License Agreement with Yale
60 Degrees Pharmaceuticals Announces 2024 Annual Results
60 Degrees Pharmaceuticals Inc trading halted, news pending

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apollomics NASDAQ:APLMW

$0.02 0.00 (-8.81%)
As of 08/14/2025 01:14 PM Eastern

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNFW

$0.46 -0.09 (-16.35%)
As of 08/14/2025 03:59 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Alpha Tau Medical stock logo

Alpha Tau Medical NASDAQ:DRTSW

$0.27 0.00 (-1.11%)
As of 08/14/2025 03:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

60 Degrees Pharmaceuticals stock logo

60 Degrees Pharmaceuticals NASDAQ:SXTPW

$0.09 -0.01 (-10.49%)
As of 08/14/2025 02:09 PM Eastern

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.